Glucagon-like peptides I and 2 in health and disease: A review

被引：69
作者：
Marathe, Chinmay S. [1 ,2 ]
Rayner, Christopher K. [1 ,2 ]
Jones, Karen L. [1 ,2 ]
Horowitz, Michael [1 ,2 ]
机构：
[1] Univ Adelaide, Royal Adelaide Hosp, Discipline Med, Adelaide, SA, Australia
[2] Univ Adelaide, Ctr Res Excellence Translating Nutr Sci Good Hlth, Adelaide, SA, Australia
来源：
PEPTIDES | 2013年 / 44卷
关键词：
Glucagon-like peptides; Postprandial glycemia; Incretin secretion; Gastric emptying; GASTRIC-INHIBITORY POLYPEPTIDE; BETA-CELL FUNCTION; TYPE-2; DIABETES-MELLITUS; PROGLUCAGON GENE-EXPRESSION; INCRETIN-BASED THERAPIES; BIPHASIC INSULIN ASPART; TWICE-DAILY EXENATIDE; GLYCEMIC CONTROL; FOOD-INTAKE; POSTPRANDIAL GLYCEMIA;
D O I：
10.1016/j.peptides.2013.01.014
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：75 / 86
页数：12
相关论文
共 161 条
[1]   The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway [J].
Abbott, CR ;
Monteiro, M ;
Small, CJ ;
Sajedi, A ;
Smith, KL ;
Parkinson, JRC ;
Ghatei, MA ;
Bloom, SR .
BRAIN RESEARCH, 2005, 1044 (01) :127-131
[2]  
Ahrén B, 2011, DIABETES OBES METAB, V13, P158, DOI 10.1111/j.1463-1326.2011.01457.x
[3]   Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].
Astrup, Arne ;
Rossner, Stephan ;
Van Gaal, Luc ;
Rissanen, Aila ;
Niskanen, Leo ;
Al Hakim, Mazin ;
Madsen, Jesper ;
Rasmussen, Mads F. ;
Lean, Michael E. J. .
LANCET, 2009, 374 (9701) :1606-1616
[4]   Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes [J].
Bagger, Jonatan I. ;
Knop, Filip K. ;
Lund, Asger ;
Vestergaard, Henrik ;
Holst, Jens J. ;
Vilsboll, Tina .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (03) :737-745
[5]   Biology of incretins: GLP-1 and GIP [J].
Baggio, Laurie L. ;
Drucker, Daniel J. .
GASTROENTEROLOGY, 2007, 132 (06) :2131-2157
[6]   Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2 [J].
Baldassano, Sara ;
Bellanca, Anna Lisa ;
Serio, Rosa ;
Mule, Flavia .
JOURNAL OF ENDOCRINOLOGY, 2012, 213 (03) :277-284
[7]  
Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P325
[8]   Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: A proof-of-concept study in healthy subjects [J].
Beglinger, C. ;
Poller, B. ;
Arbit, E. ;
Ganzoni, C. ;
Gass, S. ;
Gomez-Orellana, I. ;
Drewe, J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (04) :468-474
[9]   HAMSTER PREPROGLUCAGON CONTAINS THE SEQUENCE OF GLUCAGON AND 2 RELATED PEPTIDES [J].
BELL, GI ;
SANTERRE, RF ;
MULLENBACH, GT .
NATURE, 1983, 302 (5910) :716-718
[10]   Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea [J].
Bergenstal, Richard ;
Lewin, Andrew ;
Bailey, Timothy ;
Chang, Denise ;
Gylvin, Titus ;
Roberts, Victor .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) :65-75
12345678910